Consequently, further combined treatment regimens with PD-L1 inhibition (pembrolizumab) in the KEYNOTE-189 and 407 trials showed improved clinical outcome in NSCLC patients independent of the PD-L1 status compared to mere standard chemotherapy [15, 16]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.